In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Replimune Group (REPL – Research Report), with a price ...

The FDA accepts and grants priority review to Replimune's BLA for RP1 in combination with Opdivo for advanced melanoma. A decision is due on Jul.

Recent results raise hope of new "broad, pan-tumor platform" like Keytruda. The emerging drugs are bispecific antibodies that ...

H.C. Wainwright analyst Robert Burns raised the firm’s price target on Replimune (REPL) to $21 from $17 and keeps a Buy rating on the shares.

During a Case-Based Roundtable® event, Kathryn E. Beckermann, MD, PhD, discussed second-line regimens with event participants ...

GPCR USA is a biotech company currently developing Opdivo, an autoimmune disease treatment that generates about $10 billion in annual revenues in the market, as well as the world's first FDA-approved ...

Ameritas Advisory Services LLC increased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 9.4% in ...

The pharma expects a modest financial headwind this year from changes to Medicare prescription drug benefits under the Inflation Reduction Act.

“It took us a few minutes to accept that this pile of rubble was our home,” said Islam Dahliz, whose family was ordered by Israeli forces to evacuate Rafah in May. By Vivian Yee and Bilal ...

Trump Asserts a Muscular Vision of Presidential Power on First Day Back In a flurry of executive actions, President Trump revived disputed claims of broad presidential authority from his first ...

The Duke of Sussex's privacy case against News Group Newspapers was due to start at the High Court yesterday.

One of the show’s main stars suggests that discussions are already underway in the writer’s room for a possible season 8. Tributes have been pouring in following the passing of legendary filmmaker ...